Catalent, Inc.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Catalent, Inc. Catalent, Inc. (CTLT) operates as a leading global contract development and manufacturing organization (CDMO) that develops, manufactures, and supplies advanced delivery technologies and solutions for drugs, biologics, cell and gene therapies, and consumer health products; its core offerings span oral technologies including soft gelatin capsules, Zydis fast-dissolve tablets, modified release and immediate release solid oral dosage forms; biologics services featuring GPEx cell line development, SMARTag bioconjugation for antibody-drug conjugates, and fill-finish manufacturing; pharma services such as prefilled syringes, blow-fill-seal unit doses, respiratory formulations, and clinical supply chain management with FastChain and CTSuccess platforms; as well as self-care products leveraging OptiGel abuse-deterrent and bioavailability-enhancing technologies like OptiForm Solution Suite. The company serves pharmaceutical, biotechnology, and consumer health firms worldwide across more than 50 sites on four continents, targeting innovators from small virtual organizations to large multinationals with end-to-end support from early-stage formulation and preclinical manufacturing to commercial-scale production and packaging. Founded in 2007 with roots tracing to the 1930 invention of the rotary die softgel process, Catalent maintains its global corporate headquarters in Tampa, Florida, following a September 2025 relocation from Somerset, New Jersey to support innovation and growth alongside its long-standing St. Petersburg manufacturing facility. In December 2024, Novo Holdings A/S completed its $16.5 billion all-cash acquisition of Catalent, positioning it as a subsidiary while enabling continued focus on patient-first delivery; this transaction included the divestiture of three fill-finish sites in Italy, the US, and Belgium to Novo Nordisk A/S; Catalent also entered a strategic collaboration with IsomAb for clinical trial product supply of ISM-001 and debuted a refreshed corporate brand in late 2025 emphasizing customer service excellence.
Cartherics and Catalent Expand Commercial License Agreement
Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases
SmartCella and Catalent Sign Nonexclusive License Agreement for GMP iPSCs
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
Catalent Debuts New Corporate Brand, Elevating Customer Service Excellence by “Championing the Missions that Matter™”
Lisata Therapeutics CEO discusses Catalent deal - ICYMI
Lisata Therapeutics CEO discusses Catalent deal - ICYMI
Lisata Therapeutics inks global product license deal with Catalent
Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection
Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug
Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research
Asia-Pacific Pharmaceutical CMO Market Share Analysis, Trends and Growth Forecasts to 2030 Featuring Catalent, Recipharm, Jubilant Life Sciences and More
Prolific Machines Appoints Former Catalent Chief Scientific Officer to Board of Directors
Lisata Therapeutics talks ADC breakthrough with Catalent – ICYMI
Lisata Therapeutics signs research license with Catalent
Lisata Therapeutics Announces Research License with Catalent
Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus
Lennox International Set to Join S&P 500 and BILL Holdings to Join S&P MidCap 400
Novo Holdings completes $16.5 bln takeover of Catalent
Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say